UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net income	$ 14,788	$ 10,798	$ 14,727
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	636	655	700
Amortization	6,645	6,515	6,144
Provision for losses on accounts receivable	24	(5)	14
Amortization of operating lease assets	3	39	38
Loss/(Gain) on disposal of assets	0	1	16
Deferred income taxes	(92)	(26)	(396)
Stock-based compensation expense	166	160	113
Tax benefit attributable to exercise of stock options	39	7	23
Accounts receivable	(1,088)	617	(738)
Other receivables	(42)	45	(16)
Inventories	(485)	924	(1,686)
Prepaid expenses and other current assets	(81)	108	(16)
Accounts payable	(23)	(308)	114
Accrued expenses	713	607	(1,651)
Long-term repatriation tax payable	0	0	(330)
Net cash provided by operating activities	21,203	20,137	17,056
Cash flows from investing activities
Property and equipment	(552)	(860)	(540)
Intangible assets	0	0	(21,000)
Net cash (used in) investing activities	(552)	(860)	(21,540)
Cash flows from financing activities
Proceeds from issuance of common stock - options	560	358	283
Common stock purchased and retired	0	(6,976)	(398)
Dividends paid	(11,465)	(4,116)	(4,112)
Net cash (used in) financing activities	(10,905)	(10,734)	(4,227)
Effect of exchange rate changes on cash	(362)	260	386
Net increase (decrease) in cash and cash equivalents	9,384	8,803	(8,325)
Cash at beginning of year	51,590	42,787	51,112
Cash at end of year	60,974	51,590	42,787
Cash paid during the period for income taxes	4,617	3,186	5,304
Cash paid during the period for interest	$ 0	$ 0	$ 0